Discover and read the best of Twitter Threads about #microdose
Most recents (3)
Here is my breakdown of the new #psychedelic #microdosing paper published yesterday (tinyurl.com/mrbhk3xd) that was 🔥🔥🔥 since all these flyers were going around at the wonderland meeting👇🍄💊🚨 
Healthy males were randomised into LSD (n=40) and placebo (n=40) groups. They received 14 doses of either 10μg LSD or placebo every 3 days for 6 weeks.
Participants were naïve to MDing, but 70% in both groups had prior psychedelic experience (last use over a year ago), so by in large this was NOT a psychedelic naïve sample.
1/ #Oregon Health Authority publishes latest draft #psilocybin rules to implement Measure 109. Some early thoughts: First, the rules allow for a variation of #microdosing. Clients could consume up to 5mg and potentially leave a center after 1 hour.
oregon.gov/oha/PH/PREVENT…
oregon.gov/oha/PH/PREVENT…
2/ Under the draft rules, the minimum length of administration sessions would vary based on the dose of #psilocybin received. Clients consuming 5 - 10mg could potentially leave after 2 hours, and 15 - 25mg would require a minimum stay of 4 hours.
3/ The facilitator to client ratios will also change depending on the doses of #psilocybin received, ranging from a potential 8 clients to each facilitator for doses of 5 - 10mg to no more than 1 client for every facilitator for doses between 40 - 50mg.
Despite the importance of #blinding in medical research, most trials don't assess blinding integrity, partially because there is no method to adjust trial results for blinding integrity... until now! New preprint with implications for #microdose and #psychedelic research 🧪🧵👇
First, we define activated expectancy bias (AEB), which is an uneven distribution of expectancy effects between treatment arms due to patients recognizing their treatment allocation. AEB can be viewed as residual expectancy bias not eliminated by the trial’s blinding procedure.
The main idea behind AEB is that if treatment allocation can be deduced by participants, then, treatment expectancy can bias the outcomes in the same manner as it biases non-blinded trials, for example as in open-label trials.
